Human TNFSF14 recombinant protein (N-human IgG1-Fc)

Human TNFSF14 recombinant protein (N-human IgG1-Fc)

• DataSheet
• Material Safety Data Sheets (MSDS)

LIGHT, also known as TNFSF14 or CD258, is a newly identified member of the TNF superfamily (TNFSF14) that is expressed by activated T lymphocytes, monocytes, granulocytes, spleen cells, and immature dendritic cells. TNFSF14 / LIGHT / CD258 is a type II transmembrane protein that is known to bind 2 membrane-bound TNFSF signaling receptors: HVEM, which is predominantly expressed by T cells, and lymphotoxin β receptor (LTβR), which is expressed by stromal cells and nonlymphoid hematopoietic cells. TNFSF14 / LIGHT / CD258 also binds to a soluble nonsignaling receptor, decoy receptor 3 (DcR3), which can modulate the function of LIGHT in vivo. TNFSF14 / LIGHT / CD258 can also costimulate T cell responses via HVEM, which is constitutively expressed in most lymphocyte subpopulations, including CD4+ and CD8+ T cells. In addition, TNFSF14 / LIGHT / CD258 has been shown to suppress tumor formation in vivo and to induce tumor cell apoptosis via the up-regulation of intercellular adhesion molecule 1 and an increased lymphocyte adhesion to cancer cells. Thus, TNFSF14 / LIGHT / CD258 is being actively investigated as a possible basis for cancer treatment.Immune Checkpoint
Immune Checkpoint Proteins
Immune Checkpoint Targets Co-stimulatory Immune Checkpoint Targets Immunotherapy Cancer Immunotherapy Targeted Therapy

CD258,HVEML,LIGHT,LTg,TR2

AAK26160.1

Human Cells

A DNA sequence encoding the human TNFSF14 (AAK26160.1) (Asp74-Val240) was expressed with the Fc region of human IgG1 at the N-terminus.

Human

The recombinant human TNFSF14 consists of 427 amino acids and predicts a molecular mass of 46.7 kDa.

> 90 % as determined by SDS-PAGE.

Measured in a cell proliferation assay using human umbilical vein endothelial cells (HUVEC). The ED₅₀ for this effect is 1-4 ng/mL.